Page last updated: 2024-12-09

2-(4-chloro-3,5-dimethylphenoxy)-N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're describing a chemical compound, but the name you provided isn't quite a standard chemical name. It's likely a more descriptive name used in a specific research context. To understand its importance, we need to break it down and make some assumptions:

**Breaking Down the Name:**

* **2-(4-chloro-3,5-dimethylphenoxy)-:** This indicates a **phenol** (a benzene ring with an -OH group) with the following modifications:
* **4-chloro:** A chlorine atom is attached to the 4th position of the benzene ring.
* **3,5-dimethyl:** Two methyl groups (CH3) are attached to the 3rd and 5th positions of the benzene ring.
* **-phenoxy:** This part indicates that the phenol is connected to another molecule through an oxygen atom (-O-).
* **N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]acetamide:** This indicates an **acetamide** (a molecule containing an -NHCOCH3 group). It's attached to a phenyl ring (benzene ring) with the following modifications:
* **4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]:**
* This means a piperazine ring (a six-membered ring with two nitrogen atoms) is attached to the 4th position of the phenyl ring.
* The piperazine ring itself has a furanyl(oxo)methyl group attached to it:
* **2-furanyl(oxo)methyl:** A furan ring (a five-membered ring with an oxygen atom) with a carbonyl group (C=O) and a methylene group (CH2) attached.

**Possible Significance:**

Based on the structure, this compound likely has biological activity and is used in research for the following reasons:

* **Potential Drug Development:** The compound contains features commonly found in drugs, like the phenol and acetamide groups, which are known to interact with biological systems. The piperazine ring is often used to bind to receptors in the brain, making it a promising starting point for developing new drugs.
* **Medicinal Chemistry Studies:** Researchers may be studying this compound to investigate its biological effects, such as its ability to bind to specific proteins, its ability to cross cell membranes, or its potential therapeutic activity. This research could lead to the development of new drugs for treating various diseases.
* **Chemical Synthesis & Design:** The compound's structure might be used as a basis for designing new molecules with improved properties or activity.

**To provide a more precise answer, you would need to tell us:**

* **What is the source of this name?** Is it from a scientific paper, a patent, a chemical database, or other source?
* **What is the context of the research?** What are the researchers investigating?

Knowing this information would help us understand the specific importance of this particular compound in the research.

Cross-References

ID SourceID
PubMed CID1255242
CHEMBL ID1363851
CHEBI ID105770

Synonyms (19)

Synonym
HMS1601C09
AP-970/43336862
smr000201380
2-(4-chloro-3,5-dimethylphenoxy)-n-{4-[4-(2-furoyl)-1-piperazinyl]phenyl}acetamide
MLS000582679 ,
STK172708
2-(4-chloro-3,5-dimethylphenoxy)-n-{4-[4-(furan-2-ylcarbonyl)piperazin-1-yl]phenyl}acetamide
CHEBI:105770
AKOS000460859
MLS002548377
2-(4-chloro-3,5-dimethylphenoxy)-n-[4-[4-(furan-2-carbonyl)piperazin-1-yl]phenyl]acetamide
HMS2471L10
CHEMBL1363851
cid_1255242
2-(4-chloro-3,5-dimethyl-phenoxy)-n-[4-[4-(2-furoyl)piperazino]phenyl]acetamide
bdbm41090
2-(4-chloranyl-3,5-dimethyl-phenoxy)-n-[4-[4-(furan-2-ylcarbonyl)piperazin-1-yl]phenyl]ethanamide
2-(4-chloro-3,5-dimethylphenoxy)-n-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]acetamide
Q27183546
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency63.09570.631035.7641100.0000AID504339
WRNHomo sapiens (human)Potency17.15800.168331.2583100.0000AID651768; AID720497
ATAD5 protein, partialHomo sapiens (human)Potency1.45810.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency31.62280.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency9.76130.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency1.41250.180013.557439.8107AID1460
Smad3Homo sapiens (human)Potency0.63100.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency10.75090.00018.4406100.0000AID720579; AID720580
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
Bloom syndrome protein isoform 1Homo sapiens (human)Potency5.40630.540617.639296.1227AID720503
chromobox protein homolog 1Homo sapiens (human)Potency112.20200.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency8.19950.00419.984825.9290AID504444
DNA polymerase betaHomo sapiens (human)Potency6.30960.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency15.10140.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency82.17710.100028.9256213.3130AID588591; AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency32.91100.050127.073689.1251AID588590; AID720496
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.22390.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PTK2B protein tyrosine kinase 2 betaHomo sapiens (human)IC50 (µMol)5.95601.53704.08056.9220AID1641
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]